ProKidney Corp. Class A (PROK)

ProKidney Corp. has experienced several stock-impacting events over the past six months. Positive Phase 2 trial results for REGEN-007 led to a significant market response. The company completed its Delaware domestication and restructured corporate agreements. Analyst rating updates were received in August and December 2025. ProKidney presented strategic updates at several healthcare conferences. The Q3 2025 earnings report showed an EPS of -$0.12, exceeding expectations. Full results from the Phase 2 REGEN-007 trial were presented at the American Society of Nephrology Kidney Week 2025. Despite positive trial outcomes, the stock has experienced significant volatility and decline.

As a clinical-stage biotechnology company, ProKidney Corp. does not have commercial products generating revenue, so demand seasonality does not directly apply. The demand for rilparencel will be driven by clinical trial success, regulatory approvals, and the medical need for chronic kidney disease treatments. The biotech industry can experience volatility, but this is generally not tied to seasonal consumer demand.

ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases. Founded in 2015, it aims to shift the treatment paradigm from managing kidney failure to restoring kidney function. Their lead product candidate, rilparencel (REACT), is an autologous cellular therapy being evaluated in Phase 2 and Phase 3 clinical studies and has received RMAT designation from the FDA. The company is also developing a cryopreserved version of rilparencel.

ProKidney Corp. is headquartered in Winston-Salem, North Carolina, United States. The company's development and clinical studies for its cell therapy platform are conducted in the United States.

ProKidney's brand reputation in the past year has been shaped by its clinical trial progress and analyst coverage. Positive Phase 2 clinical trial results for rilparencel significantly boosted the company's profile, leading to a substantial increase in stock price and positive analyst initiation. The company's presentations at various healthcare conferences also contribute to its visibility. However, the company faces inherent risks, such as the uncertainty of regulatory approval and the stock's significant volatility.

ProKidney Corp. has 109 institutional owners and shareholders holding a total of 37,654,454 shares. Major institutional owners include Suvretta Capital Management, Llc, Morgan Stanley, and Vanguard Group Inc. Individual investors own 32% of the company, with Pablo Legorreta being the largest shareholder with 17% of shares outstanding, and Bruce Culleton, the CEO, holding 1.2% of the shares.